Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Rheumatology
•
Spondyloarthritis
How would you manage a patient with arthritis mutilans who has failed TNFi, IL-17i, and JAKi and now on bimekizumab and with worsening joint disease?
Related Questions
How do you decide between initiating systemic immunotherapy versus local treatment for uveitis with associated HLA-B27 and spondyloarthropathy?
Do you use biologic DMARDs for active axial spondyloarthritis in transplant patients on long-term anti-rejection therapy?
What circumstances would drive you to consider using an oral IL-23 inhibitor over parenteral options for the management of psoriasis and/or psoriatic arthritis?
What is your approach to choosing a particular advanced therapy based on patient or disease factors when initiating treatment for moderate-severe IBD?
How would you approach treatment of active axial spondyloarthritis refractory to NSAID in a patient with concurrent autoinflammatory disease on long-term anti-IL-1 therapy?
Would you recommend avoiding use of bimekizumab in patients at higher risk of fungal infections such as patients with diabetes who are on SGLT-2 inhibitors which also increase the risk of fungal infections?
Is it safe to use one TNF inhibitor (e.g., infliximab) in a patient who has had a severe allergic reaction to a different TNF inhibitor (e.g., adalimumab)?
Where do you anticipate using bimekizumab in your sequence of treatment options for a patient with psoriatic arthritis?
Do you generally attempt to taper and discontinue biologics in a patient with psoriatic arthritis who is in clinical remisson?
Do you utilize serial MRI imaging in patients with axial spondyloarthritis to ensure good disease control or do you rely on symptoms and physical exam to assess treatment response?
